Why Did Amazon Go Up So Much?
Shares of Amazon (NASDAQ:AMZN) soared late last week, bringing the…
Buy
62
EW Quote, Financials, Valuation and Earnings
Last price:
$82.45
Seasonality move
:
9.58%
Day range:
$82.54 - $84.54
52-week range:
$64.89 - $87.09
Dividend yield:
0%
P/E ratio:
35.32x
P/S ratio:
8.28x
P/B ratio:
4.61x
Volume:
3.9M
Avg. volume:
5.1M
1-year change:
24.22%
Market cap:
$48.6B
Revenue:
$5.4B
EPS (TTM):
$2.35
Analysts' Opinion
-
Consensus RatingEdwards Lifesciences Corp. has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 14 Buy ratings, 14 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $93.59, Edwards Lifesciences Corp. has an estimated upside of 12.97% from its current price of $82.84.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $83.00 representing -0.19% downside risk from its current price of $82.84.
Fair Value
-
According to the consensus of 28 analysts, Edwards Lifesciences Corp. has 12.97% upside to fair value with a price target of $93.59 per share.
EW vs. S&P 500
-
Over the past 5 trading days, Edwards Lifesciences Corp. has overperformed the S&P 500 by 0.83% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Edwards Lifesciences Corp. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Edwards Lifesciences Corp. has grown year-over-year revenues for 6 quarters straight. In the most recent quarter Edwards Lifesciences Corp. reported revenues of $1.6B.
Earnings Growth
-
Edwards Lifesciences Corp. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Edwards Lifesciences Corp. reported earnings per share of $0.50.
Enterprise value:
45.3B
EV / Invested capital:
--
Price / LTM sales:
8.28x
EV / EBIT:
28.44x
EV / Revenue:
7.71x
PEG ratio (5yr expected):
0.06x
EV / Free cash flow:
78.45x
Price / Operating cash flow:
84.33x
Enterprise value / EBITDA:
26.70x
Gross Profit (TTM):
$4.6B
Return On Assets:
10.18%
Net Income Margin (TTM):
22.72%
Return On Equity:
14.66%
Return On Invested Capital:
12.36%
Operating Margin:
27.37%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $5.3B | $5.3B | $5.9B | $1.4B | $1.6B | |
| Gross Profit | $4.1B | $4.2B | $4.6B | $1.1B | $1.2B | |
| Operating Income | $1.5B | $1.5B | $1.6B | $377.3M | $425.1M | |
| EBITDA | $1.7B | $1.6B | -- | $411.8M | -- | |
| Diluted EPS | $2.34 | $6.93 | $2.35 | $5.13 | $0.50 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $3.5B | $3.5B | $4.1B | $6.7B | -- | |
| Total Assets | $8.2B | $8.6B | $9.4B | $13B | -- | |
| Current Liabilities | $966.5M | $917.9M | $1.2B | $1.9B | -- | |
| Total Liabilities | $2.6B | $2.4B | $2.6B | $3.4B | -- | |
| Total Equity | $5.5B | $6.2B | $6.7B | $9.6B | -- | |
| Total Debt | $684.1M | $663.3M | $666.8M | $682.5M | $600M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-06-30 | 2024-06-30 | 2025-06-30 | 2024-06-30 | 2025-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $940.4M | $866.1M | $794.9M | $371.5M | $290.2M | |
| Cash From Investing | -$36.1M | $291M | $2B | $124.8M | -$172.1M | |
| Cash From Financing | -$1.1B | -$591.4M | -$1.2B | -$96.6M | $52.7M | |
| Free Cash Flow | $668.7M | $551.8M | $577.9M | $286.1M | $240.9M | |
EW
Sector
Market Cap
$48.6B
$29.2M
Price % of 52-Week High
95.12%
50.02%
Dividend Yield
0%
0%
Shareholder Yield
0.43%
-1.23%
1-Year Price Total Return
24.22%
-23.96%
Beta (5-Year)
1.030
0.578
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$82.71
200-day SMA
Buy
Level
$75.36
Bollinger Bands (100)
Buy
Level
75.06 - 80.44
Chaikin Money Flow
Buy
Level
910.2M
20-day SMA
Buy
Level
$77.91
Relative Strength Index (RSI14)
Buy
Level
65.53
ADX Line
Buy
Level
29.79
Williams %R
Neutral
Level
-29.473
50-day SMA
Buy
Level
$77.68
MACD (12, 26)
Buy
Level
1.97
25-day Aroon Oscillator
Buy
Level
56
On Balance Volume
Neutral
Level
1.1B
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (11.37)
Buy
CA Score
(Annual)
Level (1.4198)
Buy
Beneish M-Score
(Annual)
Level (-2.238)
Buy
Momentum Score
Level (7)
Buy
Ohlson Score
Level (-3.9239)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through the following geographical segments: United States, Europe, Japan, and Rest of World. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.
Stock Forecast FAQ
In the current month, EW has received 14 Buy ratings 14 Hold ratings, and 0 Sell ratings. The EW average analyst price target in the past 3 months is $93.59.
-
Where Will Edwards Lifesciences Corp. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Edwards Lifesciences Corp. share price will rise to $93.59 per share over the next 12 months.
-
What Do Analysts Say About Edwards Lifesciences Corp.?
Analysts are divided on their view about Edwards Lifesciences Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Edwards Lifesciences Corp. is a Sell and believe this share price will drop from its current level to $83.00.
-
What Is Edwards Lifesciences Corp.'s Price Target?
The price target for Edwards Lifesciences Corp. over the next 1-year time period is forecast to be $93.59 according to 28 Wall Street analysts, 14 of them rate the stock a Buy, 0 rate the stock a Sell, and 14 analysts rate the stock a Hold.
-
Is EW A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Edwards Lifesciences Corp. is a Leans Bullish. 14 of 28 analysts rate the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of EW?
You can purchase shares of Edwards Lifesciences Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Edwards Lifesciences Corp. shares.
-
What Is The Edwards Lifesciences Corp. Share Price Today?
Edwards Lifesciences Corp. was last trading at $82.45 per share. This represents the most recent stock quote for Edwards Lifesciences Corp.. Yesterday, Edwards Lifesciences Corp. closed at $82.84 per share.
-
How To Buy Edwards Lifesciences Corp. Stock Online?
In order to purchase Edwards Lifesciences Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get EW Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
EW
Sector
P/E ratio
35.32x
23.01x
PEG ratio
0.06x
-0.01x
P/B ratio
4.61x
1.84x
Price / LTM sales
8.28x
1.59x
Growth Metrics
EW
Sector
Revenue growth
14.67%
5.57%
Earnings growth
-90.32%
--
Revenue (5-year growth)
4.58%
6.5%
Earnings forecast
$0.59
-$0.20
Profitability
EW
Sector
Profitability FY 2024
$4.3B
$3.8M
Return on invested capital
12.36%
-29.62%
Return on assets
10.18%
-26.99%
Return on equity
14.66%
-35.29%
Earnings Date
Last Earnings Date
Oct
30
Next Earnings Date
Feb
11
Estimated Next Earnings Date
Jan
29
Balance Sheet
EW
Sector
Total cash
$3B
$27.9M
Short term investments
$930.7M
$26.2M
Total assets
$13.1B
$81.2M
Long term debt
$600M
$5.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Leonardo DRS Stock Go Down?
Leonardo DRS (NASDAQ:DRS) is a diversified defense manufacturing business that…
Why Did Chipotle Stock Go Down?
Shares of Chipotle Mexican Grill (NYSE:CMG) have tanked in recent…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.8T
P/E Ratio: 66x
Buy
64
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Sell
44
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 37x
Alerts
Buy
92
LMND alert for Nov 6
Lemonade, Inc. [LMND] is down 4.57% over the past day.
Buy
83
RIGL alert for Nov 6
Rigel Pharmaceuticals, Inc. [RIGL] is down 4.31% over the past day.
Sell
22
TREX alert for Nov 6
Trex Co., Inc. [TREX] is down 1.57% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
